1. P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY. (23rd June 2022) Authors: Kuruvilla, J.; Armand, P.; Herrera, A. F.; Ribrag, V.; Brice, P.; Thieblemont, C.; Von Tresckow, B.; Kim, E.; Marinello, P.; Chakraborty, S.; Orlowski, R.; Zinzani, P. L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1376: LENALIDOMIDE–BASED MAINTENANCE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK MULTIPLE MYELOMA. (23rd June 2022) Authors: Pasvolsky, O.; Milton, D.; Rauf, M.; Tanner, M.; Bashir, Q.; Srour, S.; Saini, N.; Ramdial, J.; Nieto, Y.; Lee, H.; Patel, K.; Kebriaei, P.; Thomas, S.; Weber, D.; Orlowski, R.; Shpall, E.; Champlin, R.; Qazilbash, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1260 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211). (23rd June 2022) Authors: Usmani, S.; Hoering, A.; Ailawadhi, S.; Sexton, R.; Lipe, B.; Valent, J.; Rosenzweig, M.; Zonder, J.; Dhodapkar, M.; Callander, N.; Zimmerman, T.; Voorhees, P.; Durie, B.; Rajkumar, S. V.; Richardson, P.; Orlowski, R. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 855 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗